Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option

Progress in Brain Research

Volumn 180, Issue C, 2009, Pages 225-233

  Destache, Christopher J ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

Author keywords

Antiretroviral nanoparticles; Blood brain barrier; Drug penetration; HIV 1; Multidrug resistant protein; P glycoprotein

Indexed keywords

ANTIRETROVIRUS AGENT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE;

ANIMAL; BLOOD BRAIN BARRIER; BRAIN; COLLOID; DRUG DELIVERY SYSTEM; DRUG EFFECT; HIV ASSOCIATED DEMENTIA; HUMAN; METABOLISM; METHODOLOGY; NEUROPHARMACOLOGY; REVIEW; VASCULARIZATION; VIROLOGY;

AIDS DEMENTIA COMPLEX; ANIMALS; ANTI-RETROVIRAL AGENTS; BLOOD-BRAIN BARRIER; BRAIN; COLLOIDS; DRUG DELIVERY SYSTEMS; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NANOPARTICLES; NEUROPHARMACOLOGY; P-GLYCOPROTEIN;

EID: 77953416319     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)80012-X     Document Type: Article

References (62)

1. Alakhov, V., Klinski, E., Li, S., Pietrzynski, G., Venne, A., Batrakova, E., et al. (1999). Block copolymer-based formulation of doxorubicin from cell screen to clinical trials. Colloids and Surfaces. B, Biointerfaces, 16, 113-134.
2. Antinori, A., Arendt, G., Becker, J. T., Brew, B. J., Byrd, D. A., Cherner, M., et al. (2007). Updated research nosology for HIVassociated neurocognitive disorders. Neurology, 69, 1789-1799.
3. Bachmeier, C. J., Spitzenberger, T. J., Elmquist, W. F., & Miller, D. W. (2005). Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharmaceutical Research, 22, 1259-1268.
4. Banks, W. A., Freed, E. O., Wolf, K. M., Robinson, S. M., Franko, M., & Kumar, V. (2001). Transport of human immunodeficiency virus type 1 pseudoviruses across the bloodbrain barrier: Role of envelope proteins and adsorptive endocytosis. Journal of Virology, 75, 4681-4691.
5. Batrakova, E. V., Li, S., Vinogradov, S. V., Alakhov, V. Y., Miller, D. W., & Kabanov, A. V. (2001). Mechanism of pluronic effect on P-glycoprotein efflux system in bloodbrain barrier: Contributions of energy depletion and membrane fluidization. The Journal of Pharmacology and Experimental Therapeutics, 299, 483-493.
6. Blankson, J. N., Persaud, D., & Siliciano, R. F. (2002). The challenge of viral reservoirs in HIV-1 infection. Annual Review of Medicine, 53, 557-593.
7. Bobardt, M. D., Salmon, P., Wang, L., Esko, J. D., Gabuzda, D., Fiala, M., et al. (2004). Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. Journal of Virology, 78, 6567-6584.
8. Brigger, I., Dubernet, C., & Couvreur, P. (2002). Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews, 54, 631-651.
9. Calvo, P., Gouritin, B., Brigger, I., Lasmezas, C., Deslys, J., Williams, A., et al. (2001a). PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. Journal of Neuroscience Methods, 111, 151-155.
10. Calvo, P., Gouritin, B., Chacun, H., Desmaele, D., D'Angelo, J., Noel, J. P., et al. (2001b). Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharmaceutical Research, 18, 1157-1166.
11. Chun, T. W., Engel, D., Berrey, M. M., Shea, T., Corey, L., & Fauci, A. S. (1998). Early establishment of a pool of latently infected resting CD4(+) T cells during primary HIV-1 infection. Proceedings of the National Academy of Sciences, USA, 95, 8869-8873.
12. Dallas, S., Miller, D. S., & Bendayan, R. (2006). Multi-drug resistance-associated proteins: Expression and function in the central nervous system. Pharmacological Reviews, 58, 140-161.
13. d'Arminio Monforte, A., Cinque, P., Mocroft, A., Goebel, F. D., Antunes, F., Katlama, C., et al. (2004). Changing incidence of central nervous system diseases in the Euro-SIDA cohort. Annals of Neurology, 55, 320-328.
14. Davis, S. S. (1997). Biomedical applications of nanotechnology- implications for drug targeting and gene therapy. Trends in Biotechnology, 15, 217-224.
15. Destache, C. J., Belgum, T., Christensen, K., Shibata, A., Sharma, A., & Dash, A. K. (2009). Combination antiretroviral drugs in PLGA nanoparticle for HIV. BMC Infectious Diseases (submitted).
16. Eggers, C., Hertogs, K., Sturenburg, H. J., van Lunzen, J., & Stellbrink, H. J. (2003). Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS, 17, 1897-1906.
17. Eilers, M., Roy, U., & Mondal, D. (2008). MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Experimental Biology and Medicine (Maywood), 233, 1149-1160.
18. Ellis, R. J., Moore, D. J., Childers, M. E., Letendre, S., McCutchan, J. A., Wolfson, T., et al. (2002). Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Archives of Neurology, 59(6), 923-928.
19. Fiala, M., Looney, D. J., Stins, M., Way, D. D., Zhang, L., Gan, X., et al. (1997). TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Molecular Medicine, 3, 553-564.
20. Finzi, D., Hermankova, M., Peirson, T., Carruth, L. M., Buck, C., Chaisson, R. E., et al. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 278, 1295-1300.
21. Fiorillo, A., Maggi, G., Greco, N., Migliorati, R., D'Amico, A., De Caro, M. D., et al. (2004). Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin, and etoposide in children with recurrent malignant brain tumors. Journal of Neuro-Oncology, 66, 179-185.
22. Ghosn, J., Chaix, M. L., Peytavin, G., Rey, E., Bresson, J. L., Goujard, C., et al. (2004). Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS, 18, 1958-1961.
23. Giri, N., Shaik, N., Pan, G., Terasaki, T., Mukai, C., Kitagaki, S., et al. (2008). Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metabolism and Disposition, 36, 1476-1484.
24. Gollapudi, S., & Gupta, S. (1990). Human immunodeficiency virus I-induced expression of P-glycoprotein. Biochemical and Biophysical Research Communications, 171, 1002-1007.
25. Haas, D. W., Clough, L. A., Johnson, B. W., Harris, V. L., Spearman, P., Wilkinson, G. R., et al. (2000). Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Research and Human Retroviruses, 16, 1491-1502.
26. Haas, D. W., Johnson, B. W., Spearman, P., Raffanti, S., Nicotera, J., Schmidt, D., et al. (2003). Two phases of HIV RNA decay in CSF during initial days of multidrug therapy. Neurology, 61, 1391-1396.
27. Hau, P., Fabel, K., Baumgart, U., Rummele, P., Grauer, O., Bock, A., et al. (2004). Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer, 100, 1199-1207.
28. Hayashi, K., Pu, H., Tian, J., Andreas, I. E., Lee, Y. W., Hennig, B., et al. (2005). HIV-Tat protein induces P-glycoprotein expression in brain microvascular endothelial cells. Journal of Neurochemistry, 93, 1231-1241.
29. Jung, N., Lehmann, C., Rubbert, A., Knisppel, M., Hartmann, P., van Lunzen, J., et al. (2008). Relevance of the organic cation transporters 1 and 2 for antiretroviral therapy in HIV infection. Drug Metabolism and Disposition, 36, 1616-1623.
30. Kabanov, A. V., Chekhonin, V. P., Alakhov, V. Y., Batrakova, E. V., Lebedev, A. S., Melik-Nubarov, N. S., et al. (1989). The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. Micelles as microcontainers for drug targeting. FEBS Letters, 258(2), 343-345.
31. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., et al. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation, 101, 289-294.
32. Kingsley, J.D., Dou, H., Morehead, J., Ravinow, B., Gendelman, H. E., & Destache, C. J. (2006). Nanotechnology: A focus on nanoparticles as a drug delivery system. Journal of Neuroimmune Pharmacology, 1, 340-350.
33. Koukourakis, M. I., Koukouraki, S., Giatromanolaki, A., Kakolyris, S., Georgoulias, V., Velidaki, A., et al. (2000). High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas - rationale for combination with radiotherapy. Acta Oncologica, 39, 207-211.
34. Langford, D., Marquie-Beck, J., deAlmeida, S., Lassaretto, D., Letendre, S., Grant, I., et al. (2006). Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. Journal of Neurovirology, 12, 100-107.
35. Letendre, S., Marquie-Beck, J., Capparelli, E., Best, B., Clifford, D., Collier, A. C., et al. (2008). Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Archives of Neurology, 65, 65-70.
36. Letendre S. L., Ellis R. J., Everall, I., Ances, B., Bharti, A., & McCutchan, J. A. (2009). Neurologic complications of HIV disease and their treatment. Top HIV Med 17, 46-56.
37. Letendre, S. L., McCutchan, J. A., Childers, M. D., Woods, S. P., Lazzaretto, D., Heaton, R. K., et al. (2004). Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Annals of Neurology, 56, 416-423.
38. Liu, Y., Tang, X. P., McArthur, J. C., Scott, J., & Gartner, S. (2000). Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: Evidence for monocyte trafficking into brain. Journal of Neurovirology, 6, S70-S81.
39. Loscher, W., & Potschka, H. (2005). Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Progress in Neurobiology, 76, 22-76.
40. McArthur, J. C. (2004). HIV dementia: An evolving disease. Journal of Neuroimmunology, 157, 2-10.
41. Park, S., & Sinko, P. J. (2005). P-glycoprotein and multidrug resistance-associated proteins limit the brain uptake of squinavir in mice. The Journal of Pharmacology and Experimental Therapeutics, 312, 1249-1256.
42. Peracchia, M. T., Fattal, E., Desmaele, D., Besnard, M., Noel, J. P., Gomis, J. M., et al. (1999). Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. Journal of Controlled Release, 60, 121-128.
43. Peracchia, M. T., Vauthier, C., Desmaele, D., Gulik, A., Dedieu, J. C., Demoy, M., et al. (1998). Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharmaceutical Research, 15, 550-556.
44. Perloff, M. D., von Moltke, L. L., Fahey, J. M., & Greenblatt, D. J. (2007). Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. The Journal of Pharmacy and Pharmacology, 59, 947-953.
45. Persidsky, Y., Ghorpade, A., Rasmussen, J., Limoges, J., Liu, X. J., Stins, M., et al. (1999). Microglial and astrocyte chemokines regulate monocyte migration through the bloodbrain barrier in human immunodeficiency virus-1 encephalitis. American Journal of Pathology, 155, 1599-1611.
46. Petty, M. A., & Lo, E. H. (2002). Junctional complexes of the blood-brain barrier: Permeability changes in neuroinflammation. Progress in Neurobiology, 68, 311-323.
47. Polli, J. W., Jarrett, J. L., Studenberg, S. D., Humphreys, J. E., Dennis, S. W., Brouwer, K. R., et al. (1999). Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharmaceutical Research, 16, 1206-1212.
48. Roessler, B. J., & Davidson, B. L. (1994). Direct plasmid mediated transfection of adult murine brain cells in vivo using cationic liposomes. Neuroscience Letters, 167, 5-10.
49. Ronaldson, P. T., & Bendayan, R. (2006). HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Molecular Pharmacology, 70, 1087-1098.
50. Saito, R., Bringas, J. R., McKnight, T. R., Wendland, M. F., Mamot, C., Drummond, D. C., et al. (2004). Distribution of liposomes into brain and rate tumor models by convectionenhanced delivery monitored with magnetic resonance imaging. Cancer Research, 64, 2572-2579.
51. Siegal, T., Horowitz, A., & Gabizon, A. (1995). Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy. Journal of Neurosurgery, 83, 1237.
52. Smit, T. K., Brew, B. J., Tourtellotte, W., Morgello, S., Gelman, B. B., & Saksena, N. K. (2004). Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. Journal of Virology, 78, 10133-10148.
53. Solas, C., Lafeuillade, A., Halfon, P., Chadapaud, S., Hittinger, G., & Lacarelle, B. (2003). Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotheraphy, 47, 238-243.
54. Soontornmalai, A., Vlaming, M. L., & Fritschy, J. M. (2006). Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience, 138, 159-169.
55. Stormer, E., von Moltke, L. L., Perloff, M. D., & Greenblatt, D. J. (2002). Differential modulation of P-glycoprotein expression and activity by non-nucleosideHIV-1 reverse transcriptase inhibitors in cell culture. Pharmaceutical Research, 19, 1038-1045.
56. Valcour, V., & Paul, R. (2006). HIV infection and dementia in older adults. Clinical Infectious Disease, 42, 1449-1454.
57. Varatharajan, L., & Thomas, S. A. (2009). The transport of anti-HIV drugs across blood-CNS interfaces: Summary of current knowledge and recommendations for further research. Antiviral Research, 82, A99-A109.
58. Vinogradov, S. V., Bronich, T. K., & Kabanov, A. V. (2002). Nanosized cationic hydrogels for drug delivery: Preparation, properties and interactions with cells. Colloids and Surfaces. B, Biointerfaces, 16, 291-304.
59. Weiss, J., Theile, D., Ketabi-Kiyanvash, N., Lindenmaier, H., & Haefeli, W. E. (2007). Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metabolism and Disposition, 35, 340-344.
60. Weller, D. R., Brundage, R. C., Balfour, J. H. H., & Venzina, H. E. (2007). An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 848, 369-373.
61. Wolka, A. M., Huber, J. D., & Davis, T. P. (2003). Pain and the blood-brain barrier: Obstacles to drug delivery. Advanced Drug Delivery Reviews, 55, 987-1006.
62. Zhang, L., Gorset, W., Washington, C. B., Blaschke, T. F., Kroet, D. L., & Giacomini, K. M. (2000). Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metabolism and Disposition, 28, 329-334.